1 Long title: 2 Predictors of successful weaning from Veno-Arterial Extracorporeal Membrane 3 Oxygenation (V-A ECMO): A Systematic Review and Meta-analysis 4 5 Short title: Predictors of V-A ECMO weaning success 6 7 **Authorship** 8 Dr. Henry R. Hsu (1)\* 9 Dr. Praba Sekhar (2,3)\* 10 Ms Jahnavi Grover (4) 11 Dr. David H. Tian (2,5) 12 Dr. Ciaran Downey (6) 13 Dr Ben Maudlin (1) 14 Dr. Chathuri Dissanayake (6) 15 A/Prof Mark Dennis (1,6) 16 \*Dr Hsu and Dr Sekhar contributed to the paper equally as first authors. 17 18 **Affiliations** 19 1. The University of Sydney - School of Medicine, Sydney, New South Wales, Australia 20 2. Department of Anaesthesia and Perioperative Medicine, Westmead Hospital, Sydney, 21 Australia 22 3. The School of Public Health and Preventive Medicine, Monash University, Melbourne, 23 Victoria, Australia 24 4. School of Medicine - Western Sydney University, Sydney, New South Wales, Australia 25 5. Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia 26 6. Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

Correspondence

Dr. Mark Dennis

Faculty of Medicine and Health, Sydney, Australia

Missenden Road, Camperdown, Sydney, NSW 2050 Australia

Email: mark.dennis@sydney.edu.au

**ABSTRACT** 

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Background:

Venoarterial extracorporeal membrane oxygenation (V-A ECMO) use to support patients in

cardiac failure is increasing. Despite this increased use, predicting successful weaning from

ECMO can be challenging, no uniform guidelines on weaning exist. Therefore, we completed a

systematic review to evaluate prognostic factors that predict successful weaning from V-A ECMO.

Methods:

Following the PRIMSA guidelines, a systematic literature search of Medline, Embase, SCOPUS

and CENTRAL identified original research studies of patients requiring V-A ECMO where weaning

was attempted. Data was collected on demographic factors and weaning protocol, biomarkers,

haemodynamic, echocardiographic factors for the successfully weaned (SW) and not successfully

weaned (NSW) groups. Two investigators reviewed studies for relevance, extracted data, and

assessed risk of bias using the ROBINS-I tool. The study was registered on the international

prospective register of systematic reviews (PROSPERO ID# CRD42022366153).

Results:

1219 records were screened, of which 20 studies were deemed sufficient to be included in the

statistical analysis based on pre-specified criteria. Factors associated with successful weaning

were higher left ventricular ejection fraction (LVEF) (MD 9.0, 95% CI 4.1 – 13.8; p<0.001) and left

ventricular outflow tract velocity time integral (LVOT VTI) at time of weaning, (MD 1.35, 95% CI

0.28 – 2.40 lactate at admission (MD -2.5, 95%CI -3.8 – -1.1, p<0.001;), and CK-MB at admission

(MD -4.11, 95%CI -6.6 to -1.6, p=0.001). Critical appraisal demonstrated moderate-high risk of

bias owing to confounding and low sample sizes.

## Conclusion:

In patients on V-A ECMO support being assessed for weaning multi-parametric assessment is required. Moderate-high heterogeneity and low sample sizes warrant higher-quality studies to help guide decisions to wean patients from V-A ECMO.

Keywords: Extracorporeal membrane oxygenation, Extracorporeal life support, V-A-ECMO, Adults, Biomarkers, Haemodynamic, Echocardiography, Weaning, Successful

INTRODUCTION Veno-arterial (V-A) extracorporeal membrane oxygenation (ECMO) is increasingly being used (1, 2) in acute cardiac failure to provide end-organ perfusion whilst definitive treatment, myocardial recover occurs or bridge to left ventricular assist device (LVAD) or heart transplant is completed. Complications whilst on V-A ECMO support are common and effect mortality and increase with duration of support(3). Therefore, minimising duration of V-A ECMO support, where possible, is sought. However, premature withdrawal of V-A ECMO support, may result in recurrence of cardiogenic shock and effect recovering organs. Minimizing complications associated with device support with the potential for hemodynamic deterioration if support is prematurely discontinued can be challenging. The definition of successful V-A ECMO weaning has been proposed as when a patient survives for longer than 48 hours after ECMO explantation, with more, recent definitions as those having ECMO removed and not requiring further mechanical support because of recurring cardiogenic shock over the following 30 days(4, 5). Depending on the definition the proportion of V-A ECMO patients successfully weaned ranged between 30-75%(4-9). A variety of clinical, haemodynamic, biochemical and echocardiographic variables have been proposed and used to guide clinical improvement and readiness to wean(10). However, criteria and variables have not been completely reviewed to ascertain effectiveness(11) and metaanalyses as yet not completed. Therefore, we systematically reviewed a broad range of biomarkers, haemodynamic, echocardiographic and scoring systems to predict successful weaning from V-A ECMO.

# **METHODS**

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

The study was conducted as previously outlined in our registered and published protocol (PROSPERO ID# CRD42022366153) and in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines(12). Ethics approval and patient consent were not required.

## Search strategy

The search strategy is detailed in Supplementary Material. A comprehensive search of three electronic databases (Medline, Embase, SCOPUS and CENTRAL) was conducted in October 2022, which were re-run in December 2023 and March 2024 prior to final analysis and further studies retrieved for inclusion. Appropriate Boolean operators were used to combine search terms that included V-A ECMO, ECMO, extra-corporeal life support, weaning, decannulation and ECLS. The reference lists of all included studies were also reviewed to identify any additional articles, and duplicate articles were removed. Studies that were not primarily in the English language were included if they were accompanied by an English translation. There were no limitations on the publication period.

#### Study characteristics

Inclusion criteria allowed for randomized controlled trials, cohort studies, case series and conference abstracts that (1) considered adult or paediatric populations (2) involved patients who were on V-A ECMO and (3) there was an attempt to de-cannulate/wean from ECMO. Studies using ECMO as a bridge to ventricular assist device or heart transplant were excluded. Case series were included if >5 patients. Studies had to report associations between variables within the study and weaning success. Review publications, grey literature, non-English language publications, editorials, comments, letters to the editor and animal studies were excluded. Studies only assessing baseline variables with weaning success were excluded.

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

Study Selection Title and abstract screening were conducted by independent investigators (P.S. or H.H. or C.D.). Likewise, full-text screening was performed by two independent investigators (P.S. or H.H. or C.D.). All conflicts were resolved by a third, senior investigator (M.D.). The systematic review platform Covidence (www.covidence.org; Veritas Health Innovation, Melbourne, Australia) was used to facilitate the screening process. Publications found to fulfil eligibility criteria underwent data extraction. Data extraction Data was extracted from studies by two independent reviewers (P.S. or H.H. or C.D. or J.G.) using Microsoft Excel. Extracted variables included but not limited to patient demographics, weaning protocol, successful weaning definition, weaning success, various prognostic factors including biomarkers, haemodynamic, echocardiographic and scoring systems. The primary outcome was weaning success defined survival post removal of mechanical circulatory support and not requiring ventricular assist device or heart transplant. Meta-analysis was planned of predictors as appropriate. Missing data was reported as not reported. Authors were attempted to be contacted for further or missing data via email. Evaluation of risk of bias Critical appraisal of the risk of bias for individual studies was conducted using the ROBINS-I Tool (Risk of Bias in Non-Randomized Studies - of Interventions)(13). Each included study was scored by two independent investigators (P.S. or J.G. or H.H.). Any discrepancies between the two reviewers were resolved by discussion and mutual agreement. Studies of poor-quality following risk of bias assessment were not be excluded from being included in our synthesis. Where a poorquality study has contributed to a synthesized effect estimate, we explored the impact of study

quality by performing sensitivity analysis by removing the poor-quality study to observe the impact that bias has had on the synthesized effect.

## Statistical analysis

Meta-analysis was completed as per the Cochrane Handbook for Systematic Reviews of Interventions when the outcomes were reported by two or more trials (14). Statistical analysis was performed using Review Manager (version 5.3, The Cochrane Collaboration, Oxford, UK). For continuous outcomes, mean, standard deviation (SD) and sample size were extracted from each of the groups. Where studies reported median and ranges or interquartile range, derived mean and standard deviation as described by Wan et al. were calculated. (15). Mean differences with 95% confidence interval (CI) were used for continuous outcomes. An inverse variance method was applied for mean difference. Heterogeneity was assessed using I² statistics and values between 50% and 90% were considered to represent substantial heterogeneity. A random effects meta-analysis model and exploring heterogeneity with sensitivity and subgroup analysis were applied where appropriate. Categorisation of reported risk factors of successful weaning from studies that reported multivariable adjustment was completed.

## **RESULTS**

#### Systematic search and study selection

The search strategy of relevant references yielded a total of 2199 references (Figure 1). After the removal of 980 duplicates, the remaining 1219 references were screened by title and abstract. A total of 62 publications were deemed to be eligible for full-text screening, of which 28 studies were excluded with reasons. A total of 34 articles were included in the final analysis, of which 20 studies were deemed sufficient to be included in the statistical analysis. Risk of bias assessment is summarised in Figure 2. The remaining 14 studies examined differing prognostic predictors that

were not able to be meta-analysed together. The sample sizes ranged from 12 to 265 patients, with a pooled sample size of 1903 patients. Twenty-six publications were retrospective cohort studies, seven were prospective cohort studies, and one not recorded. Cardiogenic shock was the primary indication for V-A ECMO in ten publications, myocarditis in two, cardiomyopathy in two, cardiac arrest in four, pulmonary embolism in one, post cardiac surgery in two, congenital heart disease in one, acute respiratory distress syndrome in one, and eleven not recorded. Geographically, fourteen publications were from Asia, eight were from North America, eleven were from Europe, and one was from the Middle East. A summary of the baseline characteristics of included papers and clinical variables is provided in Table 1.

Figure 1: PRISMA flow diagram illustrating the number of studies identified by the search and the stages in which they were chosen and eliminated

Figure 2: Risk of bias of the included studies (ROBINS-I)

Author	Country	Enrol	Type of	Total	Succeeful					Male		national lic	Heart failure	Indication for V-A-ECMO	Successful wasning	Weaning success
Author	Country	Enrol ment perio d	Type of study	Total number of patients	Successful weaned	Unsuccessful wean	A	ge		wale		DIVII	Heart failure (co- morbidity)	Indication for V-A-ECMO (%)	Successful weaning definition	Weaning success
							Success wean	Unsucces s wean	Succe ss wean	Unsucces s wean	Success wean	Unsuccess wean				
Aissaoui 2011 (16)	France	2007– 2008	Prospective cohort	38	25	13	49 ± 14	67 ± 11	25	8	NR	NR	8	CMP (47%), FM (6%), Post- cardiotomy shock (22%), Post-transplantation (10%), Other (16%)	ECMO remoV-Al and no further MCS because of recurring CS over the following 30 days	20/38=53%
Akin 2017 (29)	Netherland s	2014– 2016	Prospective cohort	13	10	3	56 ± 17	41 ± 16	9	1	NR	NR	0	PE (38%), Post-cardiotomy shock (23%), CS post-AMI (15%), Myocarditis (15%), Intoxication (8%)	Successful V-A-ECMO explantation within 48 h	10/13=77%
ksoy 2024(16)	Turkey	2010- 2019	Retrospective cohort	55	27	28	2.3	1.6	19	20	NR	NR	NR	Post-op complications following congenital heart surgery, including: low cardiac output syndrome, inability to wean from bypass, ECPR.	Wean trial when adequate myocardial contraction and haemodynamically stable; initiated with flow rate to 25%	27/55 = 49%
Chen 2022 (17)	Taiwan	NR	Retrospective cohort	47	31	16	69 ± 16	39 ± 18	15	9	NR	NR	NR	NR	Weaning from ECMO and surviV-Al beyond 48 h	31/47=66%
Colombo 2019 (31)	Italy	2013– 2017	Retrospective cohort	25	18	7	NR	NR	NR	NR	NR	NR	NR	CPR (71%), CS post-AMI (17%), Myocarditis (7%), PE (4%), Takotsubo (2%), Intoxication (2%)	Device remoV-Al without requirement for re- cannulation over the following 30 days	18/25=72%
Cusanno 2022 (25)	France	2016- 2021	Retrospective cohort	57	36	21	46 ± 19	57 ± 17	NR	NR	26 ± 6	25 ± 7	37	Ischemic CS (35%), Refractory CA (28%), Other (37%)	NR	36/57=63%
Daftari 2010 (27)	USA	2000- 2008	Retrospective cohort	27	16	11	NR	NR	NR	NR	NR	NR	27	Heart failure (100%)	NR	16/27=59%
unton 2023(17)	USA	2016- 2021	Retrospective cohort	265	140	125	59.1 ± 13.6	59.4 ± 13.2	95	100	30.8 ± 8.1	30.4 ± 7.4	75	CPR, cardiogenic shock, post cardiotomy shock	Survival to decannulation	140/265 = 53%
Finnigan 2020 (32)	United Kingdom	NR	NR	14	NR	NR	NR	NR	NR	NR	NR	NR	NR	Post cardiac surgery support (57%), Respiratory support (43%)	NR	NR
rederiksen 2018 (26)	Denmark	NR	Retrospective cohort	29	15	14	NR	NR	NR	NR	NR	NR	NR	NR	ECMO weaning and being alive 24 h later without hemodynamic MCS	15/29 =52%
onzalez Martin 2021 (33)	Spain	2013– 2020	Retrospective cohort	85	52	33	NR	NR	NR	NR	NR	NR	0	CS (47%), ECPR (9%), Electrical storm (9%), Post- cardiotomy CS (33%), Other (1%)	Survival>24 h after explant and no mortality from cardiogenic shock/heart failure or cardiac arrest during admission	52/85=61%
Huang 2018 (28)	Taiwan	2014– 2015	Retrospective cohort	46	28	18	59 ± 16	48 ± 15	18	15	NR	NR	8	CS/Cardiac arrest post AMI (50%), Dilated cardiomyopathy (15%), VT/VF Arrest (11%), Myocarditis (8%), PE (4%)	ECMO removal and no mortality and/or MCS because of recurring CD over the following 48 h	28/46=61%
utchins 2023(18)	USA	2015- 2021	Retrospective cohort	199	103	96	56.2 ± 14.6	53.1 ± 16.2	67	71	NR	NR	NR	Cardiogenic shock	Successful decannulation was defined as survivall without relapse to mechanical circulatory support or heart transplant within 30 days	103/199 = 51.8%
Joseph 2019 (34)	USA	NR	Retrospective cohort	30	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Kellnar 2024 (19)	Germany	2021- 2023	Prospective cohort	12	7	5	53.0 (IQR 47.0; 60.0)	58.0 (IQR 57.5; 67.0)	NR	NR	26.9 (IQR 25.2; 30.0)	24.9 (IQR 23.7; 26.9)	NR	Cardiogenic shock	Not requiring further mechanical circulatory support within 30 days	7/12= 58%
Kim 2021 (A) (24)	South Korea	2016– 2018	Prospective cohort	92	64	28	60 ± 12	59 ± 12	48	21	24 ± 3	25 ± 4	NR	CS post-AMI (48%) Ischemic cardiomyopathy (48%), Other (4%)	ECMO removal and not requiring further MCS over the following 30 days	64/92=70%
Kim 2021 (B) (18)	South Korea	2016– 2019	Prospective cohort	79	50	29	63 ± 13	58 ± 12	41	23	25 ± 3	25 ± 4	NR	Post-MI CMP (52%), Idiopathic dilated CMP (18%), Fulminant myocarditis (4%), Stress-induced CMP (4%)	Successful removal of V- A-ECMO and no further mechanical circulatory support in the following 30 days	50/79=63%
L'Acqua 2019 (19)	Italy	2012- 2018	Retrospective cohort	98	49	49	NR	NR	NR	NR	NR	NR	NR	NR	Patient weaned from V-A ECMO	49/98 = 50%
Lee 2023(20)	South Korea	2017- 2019	Retrospective cohort	55	38	17	NR	NR	NR	NR	NR	NR	NR	NR	NR	38/55=69%
Lim 2019 (35)	South Korea	2010– 2018	Retrospective cohort	122	72	50	57.8 ± 15.0	NR	NR	NR	NR	NR	NR	NR	NR	72/122=59%
latsumoto 2018 (13)	Japan	1995– 2014	Retrospective cohort	37	22	15	44 ± 32	40 ± 31	13	8	21 ± 3	22 ± 4	NR	Myocarditis (100%)	ECMO removal	22/37=59%
ongkolpun 2019 (38)	Belgium	NR	Retrospective cohort	22	12	10	NR	NR	NR	NR	NR	NR	NR	CS post-AMI (64%), post- cardiotomy (14%), Myocarditis (14%), PE (8%)	ECMO removal and HD Stabilization without the need to increase the Vasopressor dose within 24 h	12/22=55%

Japan	1996– 2008	Retrospective cohort	25	18	7	54 ± 14	49 ± 18	8	5	NR	NR	3	Myocarditis (52%), CS post- AMI (36%), ACHF (12%)	ECMO weaning	18/25=72%
Japan	NR	Retrospective cohort	30	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	V-A-ECMO weaned of without severely deteriorated cardiac output indicated by ETCO2-10 mmHg or LVET<100 ms	NR
USA	2012- 2017	Retrospective cohort	60	42	18	NR	NR	NR	NR	NR	NR	NR	NR	V-A-ECMO decannulation	42/60 = 70%
USA	NR	Prospective cohort	12	9	3	NR	NR	NR	NR	NR	NR	NR	NR	ECMO removal without requiring any further MCS	9/12=75%
USA	2010- 2018	Prospective cohort	63	25	38	58 ± 21	32 ± 40	16	20	NR	NR	NR	Congenital heart defect (63%), Myocarditis (15%), Idiopathic dilated cardiomyopathy (14%), Sepsis (2%), Others (6%)	wean within 48 hours of assessment and survived without ventricular assist devices or orthotopic heart transplantation	25/63=40%
Japan	2013– 2017	Retrospective cohort	50	24	26	76 ± 21	64 ± 29	20	17	23 ± 6	23 ± 6	5	CS post-AMI (54%) FM (24%) CMP (10%) other heart disease (12%)	ECMO removal and survival beyond 30 days without needs for further MCS	24/50=48%
USA	2010- 2013	Retrospective cohort	23	15	8	NR	NR	NR	NR	NR	NR	NR	ARDS (100%)	NR	15/23=65%
Japan	2012– 2016	Retrospective cohort	55	28	27	64 ± 14	68 ± 16	21	25	25 ± 4	25 ± 5	NR	CS post-AMI (100%)	ECMO removal	28/55=51%
Japan	2011- 2018	Retrospective cohort	74	37	37	NR	NR	NR	NR	NR	NR	NR	NR	Patient survives more than 48 h after the removal of cannulas of ECMO	37/74 = 50%
Thailand	2018- 2021	Retrospective cohort	57	46	11	NR	NR	NR	NR	NR	NR	NR	Cardiogenic shock	NR	46/57=81%
Germany	2017- 2020	Retrospective cohort	40	16	24	51 ± 17	60 ± 15	10	18	28 ± 6	27 ± 6	NR	Cardiac arrest (40%), Cardiogenic shock (60%)	V-A-ECMO decannulation and subsequent discharge	16/40 = 40%
Japan	2010- 2016	Retrospective cohort	41	17	24	70.6±13.2	68.0±14.5	12	17	NR	NR	NR	NR	Survival for more than 24 hours after V-A-ECMO withdrawal without requiring reintroduction	17/41=41%
	Japan  USA  USA  USA  USA  Japan  Japan  Thailand  Germany	USA 2012- 2017 USA NR USA 2010- 2018  USA 2010- 2018  USA 2010- 2013  Japan 2013- 2017  USA 2010- 2018  Thailand 2018- 2021  Germany 2017- 2020  Japan 2017-	2008   Cohort	2008   Cohort	Japan	Description   Description	Japan   NR   Retrospective cohort   30   NR   NR   NR   NR	Japan   NR   Retrospective cohort   30   NR   NR   NR   NR   NR   NR	2008   Cohort   2008   Cohort   2008   Cohort   2009   2009   2019   2	Japan   NR   Retrospective cohort   30   NR   NR   NR   NR   NR   NR   NR   N	Japan   NR   Retrospective   30   NR   NR   NR   NR   NR   NR   NR   N	Japan	Japan	Mail   Mail	Light   Ligh

#### Table 1: Characteristics of included studies

ACHF acute on chronic heart failure, AMI acute myocardial infarction, ARDS acute respiratory distress syndrome, CA Cardiac arrest, CMP cardiomyopathy, CPR cardiopulmonary resuscitation, CS cardiogenic shock, ECMO extracorporeal membranous oxygenation, FM fulminant myocarditis, MCS mechanical cardiac support, NR not reported, PE pulmonary embolism, VF ventricular fibrillation, VT ventricular tachycardia

### Biomarkers

Markers of organ damage were inversely associated with weaning success – Figure 3. Lower levels of creatinine kinase (CK-MB) (MD -4.1, 95%Cl -6.6 – -1.6, p=0.001;  $I^2$  = 24%), lactate at admission (MD -2.5, 95%Cl -3.8 – -1.1, p<0.001;  $I^2$  =85%), and lower levels of alanine aminotransferase (ALT) (MD -36.7, 95%Cl -65.5 – 7.9, P=0.01;  $I^2$  = 0%) at the time of weaning

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

were associated with weaning success. Too few studies reported NT-ProBNP or Troponin to enable analysis. Figure 3 Forrest plot of comparison of haemodynamic parameters on V-A ECMO Weaning Haemodynamics Patients with higher pulse pressure (MD 13.1, 95%Cl 7.7 – 18.5, p<0.001; l<sup>2</sup> = 44%) and systolic blood pressure (MD 15.7, 95%Cl 5.4 – 25.9, p<0.001;  $I^2$  = 86%) were associated with weaning success – Figure 4. Figure 4 Forrest plot of comparison of laboratory parameters on V-A ECMO Echocardiography Patients with higher left ventricular ejection fraction (LVEF) at time of weaning (MD 9.0, 95% CI 4.1 – 13.8; p<0.001; l<sup>2</sup> = 85%), left ventricular outflow tract velocity time integral (LVOT VTI) (MD 1.35, 95% CI 0.28 – 2.40, p=0.01;  $I^2 = 0\%$ ), E/Ea (MD -2.72, 95% CI -4.45 - -0.98, p=0.002;  $I^2 = 0\%$ ) 29%) were associated with weaning success – Figure 5. Figure 5 Forest plot of the comparison of different echocardiographic parameters on V-A **ECMO** weaning Multi-variable adjusted: Risk predictors Thirteen studies provided multi-variable adjusted analysis to identify predictors of successful weaning. Covariates tested varied widely between studies; only lack of renal failure or CRRT during ECMO, and post-weaning lactate, reported by more than one study as predictors of successful ECMO weaning – Table 2.

Baseline characteristics	Study
Normal RV function	Puerto(24)
No pre-existing ischemic cardiopathy	Cusanno(9)
Post PCI TIMI flow	Sugiura(25)
While on ECMO	
No CRRT	Kim(26)
No need for LV venting	Kim (26)
10% improvement of tricuspid S' during ECMO flow study	Kim(27)
Any improvement of lateral e' during ECMO flow study	Kim(27)
ECMO duration	Punn(28)
Implantation-weaning test delay < 7 days	Cusanno(9)
Echo findings on weaning	
VTI	Lim(29), Punn(28)
LV EF	Punn(28)
Corrected LV ejection time/PAWP	Sawada(30)
Tricuspid annular S'/RSVP > 0.33	Kim(26)
RV EF	Huang(31)
Normal RV function	Puerto(24)
RV free wall strain	Huang(31)
RV FAC	Huang(31)
Hemodynamics	
HR on day of decannulation	Liu(32)
MAP at weaning	Lim(29)
MAP at 4hrs	Sugiura(25)
Post-test SBP > 120 mmHg	Cusanno(9)
CVP on day of decannulation	Huang(31)
Post de-cannulation	
Lactate at 12hrs	Chen(33)
Lactate at 24hrs	Sugiura(25)
Lower vasoactive-inotropic score 24hrs post cannulation	Dunton(17)
Improvement of RV systolic function > 24hrs after decannulation	Puerto(24)

Table 2. Risk factors predictive of successful ECMO weaning from multi-variable logistic regression models. CRRT, continuous renal replacement therapy; CVP, central venous pressure; ECMO, extracorporeal membrane oxygenation; EF, ejection fraction; FAC, fractional area change; HR, heart rate; LV, left ventricle; MAP, mean arterial pressure; PAWP, pulmonary artery wedge pressure; PCI, percutaneous coronary intervention; RV, right ventricle; SBP, systolic blood pressure; TIMI, Thrombolysis in Myocardial Infarction score; VTI, velocity time integral.

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

Study quality A total of 34 publications were eligible for quality assessment, of which 12 publications were of poor quality, i.e. 'critical' risk of bias (Figure 2). Many studies did not provide detailed protocols, limiting methodological assessment, appraisal of the confounding effect of intervention and bias in selection of participants into the study. **DISCUSSION** In this systematic review of predictors of V-A ECMO weaning success 34 predominantly small observational, studies were identified. On pooled analysis, lower levels of biochemical markers of end-organ perfusion or injury (lactate, CK-MB and ALT), haemodynamic (pulse pressure and systolic blood pressure) and echocardiographic indicators of myocardial function (LVEF, LVOT VTI, E/Ea) were associated with successful weaning form V-A ECMO. To our knowledge this review is only the second to systematically assess predictors of V-A ECMO wean success. The first, in adult patients with specifically cardiogenic shock or cardiac arrest identified similar results to our review, with lower creatine kinase and lactate levels, and higher LVEF being predictors for successful weaning from V-A-ECMO (10) Other, non-systematic, reviews have reported also reported lower creatine kinase and lactate levels, and higher LVEF and LVOT VTI being predictors for successful weaning from V-A-ECMO (34). Several other Vvariables used in clinical practice (9) i.e. Troponin, NT-ProBNP, RV to PA coupling indices were not identified owing to limited numbers of studies and patients reported with these. Despite significant heterogeneity, small sample sizes and a significant risk of bias, there are some conclusions that can be drawn from this review and the available literature. First, determination of likely weaning success, should consider multiple variables and not be focussed on one

individual predictor. Factors associated with success (or failure), were present across clinical, biochemical, haemodynamic and echocardiographic parameters and clinicians should avoid relying on one variable over the complete picture of the patient. Second, initial severity of illness (e.g. lactate), markers of end-organ perfusion, and then recovery of such are important considerations in attempting to wean (25, 35, 36). Further, absolute cut offs for specific variables e.g. LVEF or LVOT VTI to predict weaning success vary between studies, are based empirical clinical weaning protocols (34, 37) and therefore cannot yet be elucidated. Overall restitution and improvement of the overall clinical state of the patient as well as cardiac function is likely key to successful weaning rather than a specific variable or level of a variable.

Formal weaning or "ramp" studies that assess haemodynamic and echocardiographic changes to alterations to ECMO flows protocols are recommended (38) but as yet no standardised protocols exist, are only variably reported in ECMO trials, and are not formally assessed in this systematic review. However, they are critical tools to assess the response of cardiac function to reduction, and then removal, of mechanical circulatory support (9, 39). Future prospective clinical trials should publish weaning strategies and protocols to enable further assessment and comparison of strategies.

## Limitations

Our review is limited by the lack of large high-quality trial, with all included studies consisting of observational studies with small sample sizes and these small trials were used to investigate widely varying interventions amongst this population group, often performed without covariate adjustment. However, we completed a comprehensive review of the literature including all commonly used variables for V-A ECMO weaning. Micro-circulation indices were not assessed but are not in uniform clinical practice which was our focus.

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303 304

305

306 307

308

309

310

**CONCLUSIONS** patients requiring V-A ECMO support, multiple biochemical, haemodynamic and echocardiographic parameters of recovery, rather than a single variable should be used to guide appropriateness for weaning. Further larger studies are required to determine optimal weaning strategies. **AUTHOR CONTRIBUTIONS** Praba Sekhar, Henry Hsu and Mark Dennis conceived and designed the project. Praba Sekhar, Henry Hsu, Ciaran Downey and Jahnavi Grover conducted the systematic review with guidance from Mark Dennis. Praba Sekhar, Jahnavi Grover and Mark Dennis drafted the manuscript. Chathuri Dissanayake and Ben Maudlin provided critical clinical input and advice with the manuscript. All authors read, edited, and approved the final manuscript prior to submission. **ACKNOWLEDGMENTS** Although this project received no specific funding, one author is currently supported by funding from the National Heart Foundation of Australia and The University of Sydney (M.D.). **CONFLICT OF INTEREST** None of the authors has any conflict of interest to disclose. **ORCID** Praba Sekhar 0000-0003-2495-6739 Henry Hsu 0009-0001-8733-1309 **David Tian** 0000-0002-5213-9499 Mark Dennis 0000-0002-1281-1324

## References

311

- 313 1. Schrage B, Becher PM, Gossling A, Savarese G, Dabboura S, Yan I, et al. Temporal
- 314 trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic
- 315 shock. ESC Heart Fail. 2021;8(2):1295-303.
- 316 2. Mebazaa A, Combes A, van Diepen S, Hollinger A, Katz JN, Landoni G, et al.
- 317 Management of cardiogenic shock complicating myocardial infarction. Intensive Care Med.
- 318 2018;44(6):760-73.
- 319 3. Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frati G, et al. A meta-analysis
- of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc.
- 321 2013;15(3):172-8.
- 322 4. Chen YS, Chao A, Yu HY, Ko WJ, Wu IH, Chen RJ, et al. Analysis and results of prolonged
- resuscitation in cardiac arrest patients rescued by extracorporeal membrane oxygenation. J Am
- 324 Coll Cardiol. 2003;41(2):197-203.
- 325 5. Chang WW, Tsai FC, Tsai TY, Chang CH, Jeng CC, Chang MY, et al. Predictors of
- mortality in patients successfully weaned from extracorporeal membrane oxygenation. PLoS One.
- 327 2012;7(8):e42687.
- 328 6. Cavarocchi NC, Pitcher HT, Yang Q, Karbowski P, Miessau J, Hastings HM, et al.
- 329 Weaning of extracorporeal membrane oxygenation using continuous hemodynamic
- transesophageal echocardiography. J Thorac Cardiovasc Surg. 2013;146(6):1474-9.
- 331 7. Aso S, Matsui H, Fushimi K, Yasunaga H. In-hospital mortality and successful weaning
- 332 from venoarterial extracorporeal membrane oxygenation: analysis of 5,263 patients using a
- national inpatient database in Japan. Crit Care. 2016;20:80.
- 334 8. Pappalardo F, Pieri M, Arnaez Corada B, Ajello S, Melisurgo G, De Bonis M, et al. Timing
- and Strategy for Weaning From Venoarterial ECMO are Complex Issues. J Cardiothorac Vasc
- 336 Anesth. 2015;29(4):906-11.

- 337 9. Cusanno A, Aissaoui N, Minville V, Porterie J, Biendel C, Volle K, et al. Predictors of
- weaning failure in case of VA ECMO implantation. Sci Rep. 2022;12(1):13842.
- 339 10. Charbonneau F, Chahinian K, Bebawi E, Lavigueur O, Levesgue E, Lamarche Y, et al.
- 340 Parameters associated with successful weaning of veno-arterial extracorporeal membrane
- oxygenation: a systematic review. Crit Care. 2022;26(1):375.
- 342 11. Lusebrink E, Stremmel C, Stark K, Joskowiak D, Czermak T, Born F, et al. Update on
- Weaning from Veno-Arterial Extracorporeal Membrane Oxygenation. J Clin Med. 2020;9(4).
- 344 12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
- 345 PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg.
- 346 2021;88:105906.
- 347 13. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al.
- 348 ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ.
- 349 2016;355:i4919.
- 350 14. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance
- for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews
- of Interventions. Cochrane Database Syst Rev. 2019;10(10):ED000142.
- 353 15. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from
- the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
- 355 16. Aksoy T, Arslan AH, Ugur M, Ustunsoy H. Lactate and Lactate Clearance Are Predictive
- 356 Factors for Mortality in Patients with Extracorporeal Membrane Oxygenation. Braz J Cardiovasc
- 357 Surg. 2024;39(2):e20230091.
- 358 17. Dunton K, Weeks PA, Gulbis B, Jumean M, Kumar S, Janowiak L, et al. Evaluation of
- 359 Vasoactive-Inotropic Score and Survival to Decannulation in Adult Patients on Venoarterial
- 360 Extracorporeal Life Support: An Observational Cohort Study. ASAIO J. 2023;69(9):873-8.
- 361 18. Hutchins E RA, Feng J, Chandra N, Hsu JJ, Bui A. Abstract 13293: Predicting Successful
- 362 ECMO Decannulation A Novel Machine Learning Approach. American Heart Association 2023.

- 363 19. Kellnar A, Naumann D, Scherer C, Lusebrink E, Joskowiak D, Peterss S, et al. Aortic arch
- 364 blood flow measurements as a predictor of successful ECMO weaning in cardiogenic shock.
- 365 Heliyon. 2024;10(5):e26773.
- 366 20. Lee J LS, Joo S, Park Y, et al. Abstract: Pulse pressure as a potential predictive factor for
- 367 successful weaning in patients supported by Venoarterial Extracorporeal Membrane Oxygenation
- 368 without Left Ventricular Venting, ASAIO J. 2023;69:17.
- 369 21. Stull C BM, Pitcher H, Hirose H, Guarav K, Cavarocchi N. . Predictors of a successful
- wean from extracorporeal membrane oxygenation (ECMO) for ARDS. Crit Care Med. 2013;41.
- 371 22. Varodomvanichkul C, Puwatnuttasit, P, Ariyachaipanich, A. et al. . LEFT ATRIAL STRAIN
- 372 FOR PREDICTING SUCCESSFUL EXTRA-CORPOREAL MEMBRANE OXYGENATOR
- 373 WEANING FROM CARDIOGENIC SHOCK. JACC. 2023;81:686.
- 374 23. Watanabe M AY, Hasegawas S, Hamada K, Tsukamoto K, Saito T, Furuya R, Komatsu
- 375 T, Mori F. Clinical factors associated with successful venoarterial extracorporeal membrane
- 376 oxygenation weaning: A single-center retrospective cohort study. Critical Care and Shock.
- 377 2023;26:115-24.
- 378 24. Puerto E, Tavazzi G, Gambaro A, Cirillo C, Pecoraro A, Martin-Asenjo R, et al. Interaction
- between VA-ECMO and the right ventricle. Hellenic J Cardiol. 2022;68:17-24.
- 380 25. Sugiura A, Abe R, Nakayama T, Hattori N, Fujimoto Y, Himi T, et al. Predictors of
- 381 Successful Weaning From Veno-Arterial Extracorporeal Membrane Oxygenation After Coronary
- 382 Revascularization for Acute Myocardial Infarction Complicated by Cardiac Arrest: A Retrospective
- 383 Multicenter Study. Shock. 2019;51(6):690-7.
- 384 26. Kim D, Park Y, Choi KH, Park TK, Lee JM, Cho YH, et al. Prognostic Implication of RV
- 385 Coupling to Pulmonary Circulation for Successful Weaning From Extracorporeal Membrane
- 386 Oxygenation. JACC Cardiovasc Imaging. 2021;14(8):1523-31.

- 387 27. Kim D, Jang WJ, Park TK, Cho YH, Choi JO, Jeon ES, et al. Echocardiographic Predictors
- 388 of Successful Extracorporeal Membrane Oxygenation Weaning After Refractory Cardiogenic
- 389 Shock. J Am Soc Echocardiogr. 2021;34(4):414-22 e4.
- 390 28. Punn R, Falkensammer CB, Blinder JJ, Fifer CG, Thorsson T, Perens G, et al.
- 391 Hemodynamic and Echocardiographic Predictors of Mortality in Pediatric Patients on Venoarterial
- 392 Extracorporeal Membrane Oxygenation: A Multicenter Investigation. J Am Soc Echocardiogr.
- 393 2023;36(2):233-41.
- 394 29. Lim YJ JJ. Predictors of successful weaning from veno-arterial extracorporeal membrane
- 395 oxygenation support. Perfus Ger,. 2019;34:88-9.
- 396 30. Sawada K, Kawakami S, Murata S, Nishimura K, Tahara Y, Hosoda H, et al. Predicting
- 397 Parameters for Successful Weaning from Veno-Arterial Extracorporeal Membrane Oxygenation
- in Cardiogenic Shock. ESC Heart Fail. 2021;8(1):471-80.
- 399 31. Huang KC, Lin LY, Chen YS, Lai CH, Hwang JJ, Lin LC. Three-Dimensional
- 400 Echocardiography-Derived Right Ventricular Ejection Fraction Correlates with Success of
- 401 Decannulation and Prognosis in Patients Stabilized by Venoarterial Extracorporeal Life Support.
- 402 J Am Soc Echocardiogr. 2018;31(2):169-79.
- 403 32. Liu SF HC, Lee CK, Kao PHL. . Clinical Predictors of Successful Weaning VA-ECMO. J
- 404 Am Coll Cardiol. 2022:S29-30.
- 405 33. Chen TY CC, Hsu JY, Sheu JJ, Kuo HC, Hsu MH, et al. . Comparison of the predictive
- 406 ability of lactate and central venous blood gas in pediatric venoarterial mode extracorporeal
- 407 membrane oxygenation outcome. Pediatr Neonatol. 2022;63(5):474-83.
- 408 34. Brahmbhatt DH, Daly AL, Luk AC, Fan E, Billia F. Liberation From Venoarterial
- 409 Extracorporeal Membrane Oxygenation: A Review. Circ Heart Fail. 2021;14(7):e007679.
- 410 35. Asaumi Y, Yasuda S, Morii I, Kakuchi H, Otsuka Y, Kawamura A, et al. Favourable clinical
- 411 outcome in patients with cardiogenic shock due to fulminant myocarditis supported by
- 412 percutaneous extracorporeal membrane oxygenation. Eur Heart J. 2005;26(20):2185-92.

- 413 36. North M, Eckman P, Samara M, Chavez I, Schmidt C, Garberich R, et al. Peak troponin
- 414 predicts successful weaning from VA ECMO in patients with acute myocardial infarction
- complicated by cardiogenic shock. Int J Artif Organs. 2022;45(1):68-74.
- 416 37. Ortuno S, Delmas C, Diehl JL, Bailleul C, Lancelot A, Naili M, et al. Weaning from veno-
- arterial extra-corporeal membrane oxygenation: which strategy to use? Ann Cardiothorac Surg.
- 418 2019;8(1):E1-E8.
- 419 38. Lorusso R, Shekar K, MacLaren G, Schmidt M, Pellegrino V, Meyns B, et al. ELSO Interim
- 420 Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients.
- 421 ASAIO J. 2021;67(8):827-44.
- 422 39. Aissaoui N, Caudron J, Leprince P, Fagon JY, Lebreton G, Combes A, et al. Right-left
- 423 ventricular interdependence: a promising predictor of successful extracorporeal membrane
- 424 oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. Intensive Care
- 425 Med. 2017;43(4):592-4.





Figure 1 PRISMA Flow



Serious Moderate

No information

D2: Bias due to selection of participants.
D3: Bias in classification of interventions.
D4: Bias due to deviations from intended interventions.

D5: Bias due to missing data.

D6: Bias in measurement of outcomes. D7: Bias in selection of the reported result.

# **Heart Rate**

	Success	fully Wea	ned	Not Succe	ssfully We	eaned		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Naruke 2010	106	44	18	118	57	7	2.0%	-12.00 [-58.86, 34.86]	2010	<del>-</del>
Aissaoui 2011	95	16	20	115	19	13	17.1%	-20.00 [-32.48, -7.52]	2011	
Matsumoto 2018	106.036	37.07	22	98	37.07	15	6.6%	8.04 [-16.29, 32.36]	2018	<del></del>
Punn 2019	121.2	26.8	25	125.7	26	38	15.7%	-4.50 [-17.87, 8.87]	2019	
Sawada 2021	82	17.77	24	84	10.37	26	25.3%	-2.00 [-10.15, 6.15]	2021	-
Hutchins 2023	91.6	17.4	103	91	16	96	33.3%	0.60 [-4.04, 5.24]	2023	<u>+</u>
Total (95% CI)			212			195	100.0%	-4.14 [-10.99, 2.71]		•
Heterogeneity: Tau <sup>2</sup> =	31.10; Chi <sup>2</sup>	= 10.15, 0	df = 5 (P	= 0.07); I <sup>2</sup> =	51%					-50 -25 0 25 50
Test for overall effect:	Z = 1.18 (P	= 0.24)								Successfully Weaned Not Successfully Weaned

# Systolic Blood Pressure (mmHg)

	Succ	essfully Weane	d	Not Su	ccessfully Wea	ned		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Naruke 2010	84	31	18	85	4	7	12.1%	-1.00 [-15.62, 13.62]	2010	<del></del>
Matsumoto 2018	84	11.85185185	22	86	17.7777778	15	13.9%	-2.00 [-12.27, 8.27]	2018	-
Kim 2021 (A) JASE	100.3	10.3	64	97.3	15.4	28	15.2%	3.00 [-3.24, 9.24]	2021	<del> -</del>
Sawada 2021	114	25.18518519	24	100	25.92592593	26	12.3%	14.00 [-0.17, 28.17]	2021	-
Watanabe 2023	122.5	24.5	17	79.1	41.9	24	9.8%	43.40 [22.99, 63.81]	2023	
Hutchins 2023	116	21.6	103	93.4	22.3	96	15.3%	22.60 [16.49, 28.71]	2023	-
Lee 2023	109.4	12.3	38	81.6	17.2	17	14.3%	27.80 [18.74, 36.86]	2023	
Kellnar 2024	111.7786	16.5338	7	80.9155	29.6661	5	7.1%	30.86 [2.12, 59.61]	2024	
Total (95% CI)			293			218	100.0%	15.65 [5.44, 25.86]		•
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:			(P < 0.00	0001); I <sup>2</sup> = 8	86%					-50 -25 0 25 50 Successfully Weaned Not Successfully Weaned

# Pulse Pressure

	Succ	essfully Weane	d	Not Su	ccessfully Wear	ned		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Aissaoui 2011	52	12	38	39	19	13	15.5%	13.00 [1.99, 24.01]	2011	-
Punn 2019	33.6	14.6	25	26.6	13.7	38	24.3%	7.00 [-0.19, 14.19]	2019	
Sawada 2021	50	30.37037037	24	45	14.81481481	26	11.8%	5.00 [-8.42, 18.42]	2021	
Lee 2023	32.8	8.1	38	18.4	8.7	17	31.5%	14.40 [9.53, 19.27]	2023	-
Watanabe 2023	60.1	17.6	17	35.2	21	24	14.0%	24.90 [13.04, 36.76]	2023	
Kellnar 2024	50.6221	21.1265	7	24.3595	30.6717	5	2.9%	26.26 [-4.85, 57.37]	2024	
Total (95% CI)			149			123	100.0%	13.09 [7.65, 18.53]		•
Heterogeneity: Tau2 =	18.29; Chi	$^2 = 8.92$ , $df = 5$ (1)	P = 0.11	$   ^2 = 44\%$						50 25 50
Test for overall effect:	Z = 4.71 (F	o < 0.00001)								-50 -25 0 25 50 Successfully Weaned Not Successfully Wear

	Succ	essfully Wean	ed	Not Su	ccessfully Wea	aned		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Aissaoui 2011	7.3	5.4	38	7.3	6.1	15	7.2%	0.00 [-3.53, 3.53]	2011	
Matsumoto 2018	1.35	2.5926	22	2.8	6.68	15	7.2%	-1.45 [-5.00, 2.10]	2018	
L'Acqua 2019	8	4.9	49	11.9	4.9	49	10.8%	-3.90 [-5.84, -1.96]	2019	
Sugiura 2019	11.8	4.74074074	27	13.8	3.85185185	27	9.9%	-2.00 [-4.30, 0.30]	2019	
Kim 2021 (B) (JACimaging)	3.3	3.037	50	5.8	4.5185	29	11.0%	-2.50 [-4.35, -0.65]	2021	
Sawada 2021	1.2	0.59259259	24	1.6	0.96296296	26	13.6%	-0.40 [-0.84, 0.04]	2021	*
Chen 2022	6.5	5.2	31	9	6.1	16	7.3%	-2.50 [-6.00, 1.00]	2022	
Voigt 2022	7.7	4.5	16	11.5	4.9	24	8.4%	-3.80 [-6.75, -0.85]	2022	
Hutchins 2023	1.69	2.06	103	6.6	6.47	96	12.2%	-4.91 [-6.26, -3.56]	2023	
Watanabe 2023	1.9	1.2	17	13.1	7.4	0		Not estimable	2023	
Aksoy 2024	3.7	2.3	27	6.2	2.6	28	12.3%	-2.50 [-3.80, -1.20]	2024	
Total (95% CI)			404			325	100.0%	-2.46 [-3.83, -1.09]		•
Heterogeneity: Tau <sup>2</sup> = 3.54; Ch			.00001); I	° = 85%						-10 -5 0 5 10
Test for overall effect: Z = 3.52	P = 0.0	004)								Successfully Weaned Not Successfully Weaned

# CK-MB Max (IU/L)

Study of white washot o		fully Wean /10.1101/2024 er review) is th		Not Succes 12815; this vers			24. The copy	Mean Difference	Year	Mean Difference IV, Random, 95% CI
Matsumoto 2018	7.7	4lt is made	e available ι	inder a CC-BY	4.0 Internation	al license .	19.9%	-7.21 [-12.30, -2.12]		
Sugiura 2019	2.5	9.64	28	7.2	6.34	27	26.3%	-4.70 [-9.00, -0.40]	2019	
Voigt 2022	2.6	3.2	16	5.27	5.1	24	53.7%	-2.67 [-5.24, -0.10]	2022	-
Total (95% CI)			66			66	100.0%	-4.11 [-6.58, -1.64]		•
Heterogeneity: Tau <sup>2</sup> =			2 (P = 0.	.27); I <sup>2</sup> = 24	%					-10 -5 0 5 10
Test for overall effect: 2	Z = 3.26 (P	= 0.001)								Successfully Weaned Not Successfully Weaned

BUN

	Succ	cessfully Wean	ed	Not Su	ccessfully Wear	ned		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Matsumoto 2018	32.5	17.7777778	22	34	14.07407407	15	23.1%	-1.50 [-11.79, 8.79]	2018	
Sawada 2021	31	22.2222222	24	34	14.81481481	26	22.3%	-3.00 [-13.56, 7.56]	2021	
Chen 2022	19.6	11	31	16.2	15.1	16	29.6%	3.40 [-4.95, 11.75]	2022	<del></del>
Aksoy 2024	27.3	18.4	27	38.2	18.1	28	25.0%	-10.90 [-20.55, -1.25]	2024	
Total (95% CI)			104			85	100.0%	-2.74 [-8.89, 3.42]		-
Heterogeneity: Tau <sup>2</sup> =	15.14; Ch	$i^2 = 4.87$ , $df = 3$	(P = 0.18)	; I <sup>2</sup> = 38%						-20 -10 0 10 20
Test for overall effect:	Z = 0.87 (	P = 0.38)								Successfully Weaned Not Successfully Weaned

pΗ

	Succ	essfully Wean	ed	Not Su	ccessfully Wea	aned		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Aissaoui 2011	7.33	0.1	38	7.35	0.15	13	11.9%	-0.02 [-0.11, 0.07]	2011	<del></del>
Matsumoto 2018	7.45	0.08148148	22	7.36	0.13333333	15	12.6%	0.09 [0.01, 0.17]	2018	
L'Acqua 2019	7.33	0.1	49	7.26	0.2	49	13.3%	0.07 [0.01, 0.13]	2019	-
Sugiura 2019	7.12	0.3037037	27	7.01	0.28888889	27	8.0%	0.11 [-0.05, 0.27]	2019	<del></del>
Sawada 2021	7.46	0.05185185	24	7.47	0.1037037	26	14.2%	-0.01 [-0.05, 0.03]	2021	+
Chen 2022	7.4	0.1	31	7.4	0.1	16	13.5%	0.00 [-0.06, 0.06]	2022	+
Cusanno 2022	7.45	0.05925926	36	7.45	0.07407407	21	14.5%	0.00 [-0.04, 0.04]	2022	+
Watanabe 2023	7.44	0.08	17	7.11	0.2	24	11.9%	0.33 [0.24, 0.42]	2023	
Total (95% CI)			244			191	100.0%	0.06 [-0.00, 0.13]		•
Heterogeneity: Tau <sup>2</sup> =			(P < 0.00	0001); I² =	88%					-0.5 -0.25 0 0.25 0.5
Test for overall effect: 2	Z = 1.95 (	P = 0.05)								Successfully Weaned Not Successfully Weaned

'ALT (IU/L)

	Succ	cessfully Wean	ed	Not St	accessfully Wea	aned		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Sugiura 2019	46.5	64.07407407	27	88.5	55.92592593	27	80.5%	-42.00 [-74.08, -9.92]	2019	
Sawada 2021	41	169.6296296	24	56	61.48148148	24	15.9%	-15.00 [-87.18, 57.18]	2021	+
Chen 2022	270.7	1,107.4	31	225.1	689.3	31	0.4%	45.60 [-413.58, 504.78]	2022	-
Aksoy 2024	169	310	27	190	294	28	3.2%	-21.00 [-180.79, 138.79]	2024	
Total (95% CI)			109			110	100.0%	-36.68 [-65.46, -7.91]		. •
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:			P = 0.89);	I <sup>2</sup> = 0%						-1000 -500 0 500 1000 Successfully Weaned Not Successfully Weaned

Figure 4

## 2.7 Fractional Shortening

	Succ	cessfully Wean	ed	Not Su	ccessfully Wear	ned		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Daftari 2010	20.5	28.81481481	16	11.8	18.2962963	11	6.6%	8.70 [-9.08, 26.48]	2010	<del></del>
Matsumoto 2018	14	8.14814815	22	15.5	11.11111111	15	28.7%	-1.50 [-8.07, 5.07]	2018	<del></del>
Punn 2019	31	16.8	25	23.5	15.5	38	22.1%	7.50 [-0.73, 15.73]	2019	-
Sawada 2021	18	7.40740741	24	11	7.40740741	26	42.6%	7.00 [2.89, 11.11]	2021	-
Total (95% CI)			87			90	100.0%	4.78 [-0.04, 9.60]		•
Heterogeneity: Tau <sup>2</sup> = 9	9.82; Chi <sup>2</sup>	= 5.18, df = 3 (F	e = 0.16); I	2 = 42%						-50 -25 0 25 50
Test for overall effect: 2	Z = 1.94 (i	P = 0.05)								Successfully Weaned Not Successfully Weaned

# 2.9TAPSE

	Succ	essfully Wean	ed	Not Suc	cessfully Wea	ned		Mean Difference		Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI		
Frederiksen 2018	16	2.2222222	15	8	3.7037037	14	19.7%	8.00 [5.76, 10.24]	2018			
Huang 2018	8.7	4	28	6.9	2.1	18	20.8%	1.80 [0.03, 3.57]	2018	-		
Kim 2 medRxiv preprint doi: https:// (which was not certified	/doi.org/10 d by peer r	.1101/2024.08.30 <b>eview)</b> is the auth	.24312815; or/funder. v	this version the has ora	posted August 31	I, 2024. The cense to dis	e copyright splay the pro	holder for this preprint	2021			
Kim 2021 (B) (JACimaging)	12.8	It is made availa	ble under a	CC-BY 4.0	laternational licen	ise. 29	20.3%	1.50 [-0.50, 3.50]	2021	-		
Cusanno 2022	18	5.18518518	36	16	3.7037037	21	19.5%	2.00 [-0.32, 4.32]	2022	-		
Total (95% CI)			193			110	100.0%	2.55 [-0.09, 5.19]		-		
Heterogeneity: Tau <sup>2</sup> = 7.90; Ch	$ni^2 = 31.43$	3, df = 4 (P < 0.	00001); I2	= 87%						-10 -5 0 5 10		
Test for overall effect: Z = 1.89	(P = 0.06	6)								Successfully Weaned Not Successfully Weaned		

# 1.10 LVOT VTI

	Succe	essfully Wean	ed	Not Suc	cessfully Wea	aned		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Welght	IV, Random, 95% CI	Year	IV, Random, 95% CI
Frederiksen 2018	11.3	3.6	15	9.4	4.4	14	13.0%	1.90 [-1.04, 4.84]	2018	<del></del>
Punn 2019	7.1	3.8	25	5.8	4.1	38	28.7%	1.30 [-0.68, 3.28]	2019	+
Kim 2021 (B) (JACimaging)	8.5	4.8888889	50	7.4	5.7037037	29	18.3%	1.10 [-1.38, 3.58]	2021	-
Kim 2021 (A) JASE	10.8	4.1	64	9.4	4.6	28	28.8%	1.40 [-0.58, 3.38]	2021	-
Cusanno 2022	15	5.56	31	14	5.86	21	11.1%	1.00 [-2.18, 4.18]	2022	-
Total (95% CI)			185			130	100.0%	1.34 [0.28, 2.40]		•
Heterogeneity: Tau² = 0.00; Chi² = 0.22, df = 4 (P = 0.99); I² = 0%										4 -2 0 2 4
Test for overall effect: $Z = 2.47$								Successfully Weaned Not Successfully Weaner		

# 2.6 E/Ea

	Successfully Weaned				ccessfully We	aned	Mean Difference			Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	/ear	IV, Random, 95% CI	
Aissaoui 2011	8.7	3.4	38	9.4	4.6	13	27.6%	-0.70 [-3.42, 2.02] 2	011		
Kim 2021 (A) JASE	12.7	12.4	64	14.6	7.6	28	14.6%	-1.90 [-6.04, 2.24] 2	021		
Kim 2021 (B) (JACimaging)	9.6	8.66666667	50	14.4	5.5555556	29	22.5%	-4.80 [-7.94, -1.66] 2	021		
Cusanno 2022	7.7	4.4444444	36	11	4	21	35.3%	-3.30 [-5.54, -1.06] 2	022		
Total (95% CI)			188			91	100.0%	-2.72 [-4.45, -0.98]		•	
Heterogeneity: Tau <sup>2</sup> = 0.90; Chi <sup>2</sup> = 4.20, df = 3 (P = 0.24); I <sup>2</sup> = 29%									-10	-5 0 5	10
Test for overall effect: Z = 3.07 (P = 0.002)									Su	ccessfully Weaned Not Successfully	Weaned

## 1.4 LVEF

	Successfully Weaned			Not Successfully Weaned				Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI Y	rear_	IV, Random, 95% CI
Naruke 2010	34	19	18	20	13	7	6.2%	14.00 [0.97, 27.03] 2	2010	
Aissaoui 2011	37	11	20	10	7	13	9.5%	27.00 [20.86, 33.14] 2	2011	
Frederiksen 2018	30	3.7037037	15	20	14.81481481	14	8.6%	10.00 [2.02, 17.98] 2	2018	
Huang 2018	35	12.3	28	25.6	16.3	18	8.2%	9.40 [0.60, 18.20] 2	2018	
Sugiura 2019	10	9.03703704	27	10	7.40740741	27	10.3%	0.00 [-4.41, 4.41] 2	2019	_
Punn 2019	42.7	17.8	25	32.9	17.9	38	8.1%	9.80 [0.80, 18.80] 2	2019	
Kim 2021 (A) JASE	25.3	15.8	64	26.3	14.4	28	9.3%	-1.00 [-7.59, 5.59] 2	2021	<del></del>
Kim 2021 (B) (JACimaging)	24	11.85185185	50	23	16.2962963	29	9.2%	1.00 [-5.78, 7.78] 2	2021	<del></del>
Voigt 2022	30	2	16	23	9	24	10.6%	7.00 [3.27, 10.73] 2	2022	-
Cusanno 2022	35	14.07407407	36	24	8.14814815	21	9.7%	11.00 [5.23, 16.77] 2	2022	
Hutchins 2023	38.5	17.4	103	25.9	17.4	96	10.1%	12.60 [7.76, 17.44] 2	2023	
Total (95% CI)			402			315	100.0%	8.96 [4.12, 13.80]		•
Heterogeneity: Tau <sup>2</sup> = 54.04; Chi <sup>2</sup> = 66.74, df = 10 (P < 0.00001); I <sup>2</sup> = 85%										10 10 10 10
Test for overall effect: Z = 3.63 (P = 0.0003)										-20 -10 0 10 20 Successfully Weaned Not Successfully Weaned